Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:33:22.030Z.
Calculation as of: 2026-10-06T15:33:22.030Z.
Quote observation: 2026-10-06T15:30:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84f755396c9cc6b6c9535f897ba0f48fef5a33e79b5fb4c136097311f2feddf3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-05-08.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
EV/EBITDA RATIO AVG TTM
N/A
EV/EBITDA RATIO AVG 3Y
N/A
EV/EBITDA RATIO AVG 5Y
N/A
EV/EBITDA RATIO AVG 10Y
N/A
EV/EBITDA RATIO AVG 15Y
N/A
EV/EBITDA RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.16M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
EV/EBITDA Ratio
N/A
TTM Avg
1.21x
3Y Avg
1.21x
5Y Avg
1.21x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IM Cannabis Corp. (IMCC) | $1.20M | N/A | N/A | N/A | N/A |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.17M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.16M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.36M | N/A | N/A | N/A | N/A |
| NewcelX Ltd. (NCEL)vs › | $1.36M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 1.21x | 1.21x | 1.21x |
| NEXGEL, Inc. (NXGL)vs › | $1.40M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.40M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBITDA RATIO |
|---|---|
| 2024-05-08 | 4.71x |
| 2024-05-07 | 4.94x |
| 2024-05-06 | 4.96x |
| 2024-05-03 | 5.24x |
| 2024-05-02 | 5.31x |
| 2024-05-01 | 5.98x |
| 2024-04-30 | 5.14x |
| 2024-04-29 | 4.14x |
| 2024-04-26 | 4.12x |
| 2024-04-25 | 4.16x |
| 2024-04-24 | 4.03x |
| 2024-04-23 | 4.17x |
| 2024-04-22 | 4.26x |
| 2024-04-19 | 4.29x |
| 2024-04-18 | 4.24x |
| 2024-04-17 | 4.15x |
| 2024-04-16 | 3.99x |
| 2024-04-15 | 4.20x |
| 2024-04-12 | 4.36x |
| 2024-04-11 | 4.69x |
| 2024-04-10 | 4.73x |
| 2024-04-09 | 4.87x |
| 2024-04-08 | 5.41x |
| 2024-04-05 | 5.14x |
| 2024-04-04 | 5.88x |
| 2024-04-03 | 5.52x |
| 2024-04-02 | 4.79x |
| 2024-04-01 | 4.74x |
| 2024-03-28 | 28.21x |
| 2024-03-27 | 25.18x |
| 2024-03-26 | 26.33x |
| 2024-03-25 | 25.09x |
| 2024-03-22 | 25.56x |
| 2024-03-21 | 22.06x |
| 2024-03-20 | 22.57x |
| 2024-03-19 | 22.44x |
| 2024-03-18 | 22.78x |
| 2024-03-15 | 24.07x |
| 2024-03-14 | 23.08x |
| 2024-03-13 | 22.44x |
| 2024-03-12 | 22.23x |
| 2024-03-11 | 22.70x |
| 2024-03-08 | 22.70x |
| 2024-03-07 | 22.70x |
| 2024-03-06 | 22.74x |
| 2024-03-05 | 22.57x |
| 2024-03-04 | 22.66x |
| 2024-03-01 | 23.04x |
| 2024-02-29 | 23.04x |
| 2024-02-28 | 23.13x |
| 2024-02-27 | 23.60x |
| 2024-02-26 | 22.87x |
| 2024-02-23 | 23.13x |
| 2024-02-22 | 23.13x |
| 2024-02-21 | 24.11x |
| 2024-02-20 | 23.85x |
| 2024-02-16 | 22.53x |
| 2024-02-15 | 22.19x |
| 2024-02-14 | 22.31x |
| 2024-02-13 | 21.59x |
| 2024-02-12 | 21.80x |
| 2024-02-09 | 21.20x |
| 2024-02-08 | 21.12x |
| 2024-02-07 | 20.99x |
| 2024-02-06 | 20.78x |
| 2024-02-05 | 20.82x |
| 2024-02-02 | 20.90x |
| 2024-02-01 | 21.08x |
| 2024-01-31 | 21.29x |
| 2024-01-30 | 21.97x |
| 2024-01-29 | 22.91x |
| 2024-01-26 | 23.04x |
| 2024-01-25 | 20.09x |
| 2024-01-24 | 19.71x |
| 2024-01-23 | 19.92x |
| 2024-01-22 | 20.26x |
| 2024-01-19 | 20.48x |
| 2024-01-18 | 21.20x |
| 2024-01-17 | 21.80x |
| 2024-01-16 | 21.59x |
| 2024-01-12 | 22.14x |
| 2024-01-11 | 21.80x |
| 2024-01-10 | 22.36x |
| 2024-01-09 | 22.74x |
| 2024-01-08 | 23.17x |
| 2024-01-05 | 23.77x |
| 2024-01-04 | 23.68x |
| 2024-01-03 | 22.87x |
| 2024-01-02 | 23.34x |
| 2023-12-29 | 23.77x |
| 2023-12-28 | 23.30x |
| 2023-12-27 | 23.25x |
| 2023-12-26 | 23.38x |
| 2023-12-22 | 23.34x |
| 2023-12-21 | 23.21x |
| 2023-12-20 | 24.62x |
| 2023-12-19 | 23.08x |
| 2023-12-18 | 24.11x |
| 2023-12-15 | 24.58x |
| 2023-12-14 | 23.72x |
| 2023-12-13 | 23.81x |
| 2023-12-12 | 23.98x |
| 2023-12-11 | 24.15x |
| 2023-12-08 | 23.94x |
| 2023-12-07 | 24.15x |
| 2023-12-06 | 24.62x |
| 2023-12-05 | 25.13x |
| 2023-12-04 | 25.01x |
| 2023-12-01 | 25.18x |
| 2023-11-30 | 25.05x |
| 2023-11-29 | 25.13x |
| 2023-11-28 | 24.58x |
| 2023-11-27 | 24.79x |
| 2023-11-24 | 25.05x |
| 2023-11-22 | 24.75x |
| 2023-11-21 | 25.39x |
| 2023-11-20 | 25.13x |
| 2023-11-17 | 25.39x |
| 2023-11-16 | 25.13x |
| 2023-11-15 | 25.90x |
| 2023-11-14 | 26.03x |
